Biocompatible Polymers Combined with Cyclodextrins: Fascinating Materials for Drug Delivery Applications

Kost, Bartłomiej; Brzeziński, Marek; Socka, Marta; Baśko, Małgorzata; Biela, Tadeusz

doi:10.3390/molecules25153404

Cited by 42 publications

(25 citation statements)

References 192 publications

(265 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The latest generation of nanotransporters are the stimuli-responsive nanocarriers that are based on the exploitation of disease condition or environment to develop a system with the best diagnosis and treatment effects [ 65 ]. Several possibilities of stimuli-responsive nanosystems such as pH, temperature, redox state, or magnetic field based systems have been tested with promising efficiency [ 60 , 65 , 79 , 80 , 81 , 82 , 83 ].…”

Section: Drug Delivery Systemsmentioning

confidence: 99%

Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems

Plachá

Jampílek

2021

Pharmaceutics

View full text Add to dashboard Cite

Inflammatory diseases, whether caused by excessive stress on certain tissues/parts of the body or arising from infections accompanying autoimmune or secondary diseases, have become a problem, especially in the Western world today. Whether these are inflammations of visceral organs, joints, bones, or the like, they are always a physiological reaction of the body, which always tries to eradicate noxious agents and restore tissue homeostasis. Unfortunately, this often results in damage, often irreversible, to the affected tissues. Nevertheless, these inflammatory reactions of the body are the results of excessive stress, strain, and the generally unhealthy environment, in which the people of Western civilization live. The pathophysiology and pathobiochemistry of inflammatory/autoimmune processes are being studied in deep detail, and pharmaceutical companies are constantly developing new drugs that modulate/suppress inflammatory responses and endogenous pro-inflammatory agents. In addition to new specifically targeted drugs for a variety of pro-inflammatory agents, a strategy can be found for the use of older drugs, which are formulated into special nanodrug delivery systems with targeted distribution and often modified release. This contribution summarizes the current state of research and development of nanoformulated anti-inflammatory agents from both conventional drug classes and experimental drugs or dietary supplements used to alleviate inflammatory reactions.

show abstract

Section: Drug Delivery Systemsmentioning

confidence: 99%

Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems

Plachá

Jampílek

2021

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Molecular structure data files for SW033291 were downloaded from PubChem and cyclodextrin variants (α-CD, β-CD, and γ-CD) were isolated using Jmol v. 14 (http://www.jmol.org/, accessed on 7 October 2021) from Protein Data Bank entries 1CXF, 3CGT, and 1D3C, respectively. Previous studies have shown that "binding affinity", represented by K D , is closely correlated with the duration of drug delivery, and that drug complexation with CD does not impact the chemical properties of the drug payload [11,[18][19][20].…”

Section: In Silico "Affinity" Predictions: Cyclodextrin and Sw033291mentioning

confidence: 99%

Polymer Microparticles Prolong Delivery of the 15-PGDH Inhibitor SW033291

et al. 2021

View full text Add to dashboard Cite

As the prevalence of age-related fibrotic diseases continues to increase, novel antifibrotic therapies are emerging to address clinical needs. However, many novel therapeutics for managing chronic fibrosis are small-molecule drugs that require frequent dosing to attain effective concentrations. Although bolus parenteral administrations have become standard clinical practice, an extended delivery platform would achieve steady-state concentrations over a longer time period with fewer administrations. This study lays the foundation for the development of a sustained release platform for the delivery of (+)SW033291, a potent, small-molecule inhibitor of the 15-hydroxyprostaglandin dehydrogenase (15-PGDH) enzyme, which has previously demonstrated efficacy in a murine model of pulmonary fibrosis. Herein, we leverage fine-tuned cyclodextrin microparticles—specifically, β-CD microparticles (β-CD MPs)—to extend the delivery of the 15-PGDH inhibitor, (+)SW033291, to over one week.

show abstract

“…Cyclodextrin-polyester derivatives are highly important in the biomedical field as they combine both the properties of cyclodextrins (CDs) and of polyesters such as drug encapsulation capacity, low toxicity, biocompatibility, and biodegradability [ 1 ]. Native CDs are poorly water-soluble and the chemical modification of CDs at hydroxyl groups is often employed to improve their solubility through esterification, etherification, amination, etc.…”

Section: Introductionmentioning

confidence: 99%

Cyclodextrin-Oligocaprolactone Derivatives—Synthesis and Advanced Structural Characterization by MALDI Mass Spectrometry

Peptu¹,

Blaj²,

Balan-Porcăraşu³

et al. 2022

Polymers

View full text Add to dashboard Cite

Cyclodextrins have previously been proven to be active in the catalysis of cyclic ester ring-opening reactions, hypothetically in a similar way to lipase-catalyzed reactions. However, the way they act remains unclear. Here, we focus on β-cyclodextrin’s involvement in the synthesis and characterization of β-cyclodextrin-oligocaprolactone (CDCL) products obtained via the organo-catalyzed ring-opening of ε-caprolactone. Previously, bulk or supercritical carbon dioxide polymerizations has led to inhomogeneous products. Our approach consists of solution polymerization (dimethyl sulfoxide and dimethylformamide) to obtain homogeneous CDCL derivatives with four monomer units on average. Oligomerization kinetics, performed by a matrix-assisted laser desorption ionization mass spectrometry (MALDI MS) optimized method in tandem with 1H NMR, revealed that monomer conversion occurs in two stages: first, the monomer is rapidly attached to the secondary OH groups of β-cyclodextrin and, secondly, the monomer conversion is slower with attachment to the primary OH groups. MALDI MS was further employed for the measurement of the ring-opening kinetics to establish the influence of the solvents as well as the effect of organocatalysts (4-dimethylaminopyridine and (–)-sparteine). Additionally, the mass spectrometry structural evaluation was further enhanced by fragmentation studies which confirmed the attachment of oligoesters to the cyclodextrin and the cleavage of dimethylformamide amide bonds during the ring-opening process.

show abstract

Biocompatible Polymers Combined with Cyclodextrins: Fascinating Materials for Drug Delivery Applications

Cited by 42 publications

References 192 publications

Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems

Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems

Polymer Microparticles Prolong Delivery of the 15-PGDH Inhibitor SW033291

Cyclodextrin-Oligocaprolactone Derivatives—Synthesis and Advanced Structural Characterization by MALDI Mass Spectrometry

Contact Info

Product

Resources

About